Clinical Trial Update: Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating mechanisms of acquired resistance to panitumumab in metastatic colorectal cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Vectibix (panitumumab)

Snippet

Sponsor: NantBioScience, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-08